SkinBioTherapeutics (LON:SBTX) Issues Earnings Results

SkinBioTherapeutics (LON:SBTX) released its quarterly earnings results on Wednesday. The company reported GBX (0.46) (($0.01)) earnings per share (EPS) for the quarter, Digital Look Earnings reports. SkinBioTherapeutics had a negative return on equity of 115.86% and a negative net margin of 237.95%.

SkinBioTherapeutics Trading Up 0.4 %

Shares of LON:SBTX opened at GBX 24.20 ($0.31) on Friday. SkinBioTherapeutics has a twelve month low of GBX 8.32 ($0.11) and a twelve month high of GBX 26.45 ($0.34). The company has a current ratio of 0.93, a quick ratio of 10.01 and a debt-to-equity ratio of 27.57. The firm has a market cap of £55.28 million, a P/E ratio of -14.88 and a beta of 2.01. The company has a 50 day moving average of GBX 20.16 and a 200-day moving average of GBX 16.70.

SkinBioTherapeutics Company Profile

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis.